Cargando…

The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo

Influenza A virus (IAV) is a common pathogen of respiratory disease. The IAV-induced seasonal epidemics and the sporadic pandemics are associated with high morbidity and mortality. Therefore, effective protection and therapy for IAV infections is an important challenge in countering this public heal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schloer, Sebastian, Goretzko, Jonas, Kühnl, Alexander, Brunotte, Linda, Ludwig, Stephan, Rescher, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455256/ https://www.ncbi.nlm.nih.gov/pubmed/30866762 http://dx.doi.org/10.1080/22221751.2018.1559709

Ejemplares similares

Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro
por: Kummer, Susann, et al.
Publicado: (2022)

Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
por: Schloer, Sebastian, et al.
Publicado: (2020)

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
por: Schloer, Sebastian, et al.
Publicado: (2020)

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
por: Schloer, Sebastian, et al.
Publicado: (2021)

Repurposing Antifungals for Host-Directed Antiviral Therapy?
por: Schloer, Sebastian, et al.
Publicado: (2022)

Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
por: Brunotte, Linda, et al.
Publicado: (2021)

The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model
por: Schloer, Sebastian, et al.
Publicado: (2019)

3D Ex vivo tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseases
por: Schloer, Sebastian, et al.
Publicado: (2022)

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs
por: Schreiber, André, et al.
Publicado: (2022)

Phosphorylation of TRIM28 Enhances the Expression of IFN-β and Proinflammatory Cytokines During HPAIV Infection of Human Lung Epithelial Cells
por: Krischuns, Tim, et al.
Publicado: (2018)

Annexins in Translational Research: Hidden Treasures to Be Found
por: Schloer, Sebastian, et al.
Publicado: (2018)

The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
por: Schreiber, André, et al.
Publicado: (2022)

Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus
por: Kühnl, Alexander, et al.
Publicado: (2018)

Cholesterol Reduces Partitioning of Antifungal Drug Itraconazole into Lipid Bilayers
por: Poojari, Chetan, et al.
Publicado: (2020)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities
por: Matos, Aline da Rocha, et al.
Publicado: (2019)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication
por: Policastro, Lucca R., et al.
Publicado: (2022)

The Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A Viruses (IAV) into Host Cells
por: Eierhoff, Thorsten, et al.
Publicado: (2010)

Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis
por: Subedi, Laxman, et al.
Publicado: (2021)

Conserved cholesterol-related activities of Dispatched 1 drive Sonic hedgehog shedding from the cell membrane
por: Ehring, Kristina, et al.
Publicado: (2021)

An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis
por: Tupaki-Sreepurna, Ananya, et al.
Publicado: (2017)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
por: Wang, Li, et al.
Publicado: (2022)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Annexin A6-Balanced Late Endosomal Cholesterol Controls Influenza A Replication and Propagation
por: Musiol, Agnes, et al.
Publicado: (2013)

10122 Development of an In Vitro in Vivo Correlation of Itraconazole Spray-Dried Dispersion Tablets
por: Coutinho, Ana Luisa, et al.
Publicado: (2021)

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo
por: Konings, Mickey, et al.
Publicado: (2023)

Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement; in vitro and in vivo assessment
por: Islam, Nayyer, et al.
Publicado: (2023)

Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles
por: Qiu, Lixin, et al.
Publicado: (2015)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study
por: Lamie, Caroline, et al.
Publicado: (2022)

In vitro and in vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus fumigatus
por: Zeng, Qiuqiong, et al.
Publicado: (2019)

In vitro and in vivo assessment of hydroxypropyl cellulose as functional additive for enabling formulations containing itraconazole
por: Bachmaier, Rafael D., et al.
Publicado: (2021)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Itraconazole Loaded Biosurfactin Micelles with Enhanced Antifungal Activity: Fabrication, Evaluation and Molecular Simulation
por: Usman, Faisal, et al.
Publicado: (2023)

Giving a Hand: Synthetic Peptides Boost the Antifungal Activity of Itraconazole against Cryptococcus neoformans
por: Aguiar, Tawanny K. B., et al.
Publicado: (2023)

The antifungal effect induced by itraconazole in Candida parapsilosis largely depends on the oxidative stress generated at the mitochondria
por: Muñoz-Megías, Mª Luz, et al.
Publicado: (2023)

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
por: Li, Yanbai, et al.
Publicado: (2023)

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules
por: El-Sheridy, Nabila A., et al.
Publicado: (2021)

Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever
por: Park, Sun Hee, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6gnutkptf3nuqskik7u871dh7u